COMMUNIQUÉ DE PRESSE publié le 04/11/2024 à 13:03, il y a 17 jours 1 heure CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
COMMUNIQUÉ DE PRESSE publié le 04/11/2024 à 13:00, il y a 17 jours 1 heure CureVac to Present at the 12th International mRNA Health Conference CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRÈVE publiée le 28/10/2024 à 13:05, il y a 24 jours 1 heure CureVac présentera de nouvelles découvertes lors de la réunion annuelle du SITC Essais Cliniques Vaccin Contre Le Cancer CureVac Technologie De L'ARNm Réunion Du SITC
BRÈVE publiée le 28/10/2024 à 13:05, il y a 24 jours 1 heure CureVac to Present New Findings at SITC Annual Meeting Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
COMMUNIQUÉ DE PRESSE publié le 28/10/2024 à 13:00, il y a 24 jours 1 heure CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRÈVE publiée le 13/09/2024 à 14:02, il y a 2 mois 8 jours CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
BRÈVE publiée le 13/09/2024 à 14:02, il y a 2 mois 8 jours Le vaccin contre le cancer CVGBM de CureVac montre des résultats prometteurs dans une étude de phase 1 sur le glioblastome Étude De Phase 1 CureVac Glioblastome CVGBM Réponses Des Lymphocytes T
COMMUNIQUÉ DE PRESSE publié le 13/09/2024 à 13:57, il y a 2 mois 8 jours CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRÈVE publiée le 12/09/2024 à 13:02, il y a 2 mois 9 jours CureVac et GSK publient des données positives de phase 2 pour le vaccin à ARNm contre la grippe Vaccin Contre La Grippe Résultats De La Phase 2 Technologie De L'ARNm Partenariat GSK Étape Importante De CureVac
BRÈVE publiée le 12/09/2024 à 13:02, il y a 2 mois 9 jours CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
Publié le 21/11/2024 à 06:58, il y a 7 heures 10 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 7 heures 10 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 7 heures 10 minutes Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 18 heures Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 48 minutes Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Publié le 21/11/2024 à 13:30, il y a 38 minutes AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Publié le 21/11/2024 à 13:30, il y a 38 minutes Datametrex Secures Additional P.O. Approx $250K for IT Services
Publié le 21/11/2024 à 13:00, il y a 1 heure 8 minutes Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Publié le 21/11/2024 à 13:00, il y a 1 heure 8 minutes Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Publié le 21/11/2024 à 13:00, il y a 1 heure 8 minutes Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Publié le 21/11/2024 à 13:41, il y a 26 minutes Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Publié le 21/11/2024 à 12:35, il y a 1 heure 32 minutes audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 1 heure 52 minutes Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven